Programmable bacteria induce durable tumor regression and systemic antitumor immunity
出版年份 2019 全文链接
标题
Programmable bacteria induce durable tumor regression and systemic antitumor immunity
作者
关键词
-
出版物
NATURE MEDICINE
Volume 25, Issue 7, Pages 1057-1063
出版商
Springer Science and Business Media LLC
发表日期
2019-07-04
DOI
10.1038/s41591-019-0498-z
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- The microbiome, cancer, and cancer therapy
- (2019) Beth A. Helmink et al. NATURE MEDICINE
- SIRPα–CD47 Immune Checkpoint Blockade in Anticancer Therapy
- (2018) André Veillette et al. TRENDS IN IMMUNOLOGY
- ALX148 blocks CD47 and enhances innate and adaptive antitumor immunity with a favorable safety profile
- (2018) Steven E. Kauder et al. PLoS One
- Dual Targeting of Innate and Adaptive Checkpoints on Tumor Cells Limits Immune Evasion
- (2018) Xiaojuan Liu et al. Cell Reports
- CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma
- (2018) Ranjana Advani et al. NEW ENGLAND JOURNAL OF MEDICINE
- Engineering Microbial Living Therapeutics: The Synthetic Biology Toolbox
- (2018) Danielle B. Pedrolli et al. TRENDS IN BIOTECHNOLOGY
- Localized CD47 blockade enhances immunotherapy for murine melanoma
- (2017) Jessica R. Ingram et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Two-step enhanced cancer immunotherapy with engineeredSalmonella typhimuriumsecreting heterologous flagellin
- (2017) Jin Hai Zheng et al. Science Translational Medicine
- Targeting CD47: the achievements and concerns of current studies on cancer immunotherapy
- (2017) Yuting Huang et al. Journal of Thoracic Disease
- Synchronized cycles of bacterial lysis for in vivo delivery
- (2016) M. Omar Din et al. NATURE
- Durable antitumor responses to CD47 blockade require adaptive immune stimulation
- (2016) Jonathan T. Sockolosky et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- CD47 blockade triggers T cell–mediated destruction of immunogenic tumors
- (2015) Xiaojuan Liu et al. NATURE MEDICINE
- Programmable probiotics for detection of cancer in urine
- (2015) Tal Danino et al. Science Translational Medicine
- Measuring mRNA copy number in individual Escherichia coli cells using single-molecule fluorescent in situ hybridization
- (2013) Samuel O Skinner et al. Nature Protocols
- Cell-Based Therapeutics: The Next Pillar of Medicine
- (2013) M. A. Fischbach et al. Science Translational Medicine
- Alp7R Regulates Expression of the Actin-Like Protein Alp7A in Bacillus subtilis
- (2012) A. I. Derman et al. JOURNAL OF BACTERIOLOGY
- The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors
- (2012) S. B. Willingham et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cancer immunotherapy comes of age
- (2011) Ira Mellman et al. NATURE
- Emerging biomedical applications of synthetic biology
- (2011) Wilfried Weber et al. NATURE REVIEWS GENETICS
- Synthetic Biology Moving into the Clinic
- (2011) W. C. Ruder et al. SCIENCE
- From DNA to Targeted Therapeutics: Bringing Synthetic Biology to the Clinic
- (2011) Y. Y. Chen et al. Science Translational Medicine
- Inhibition of Tumor Growth and Metastasis by a Combination of Escherichia coli –mediated Cytolytic Therapy and Radiotherapy
- (2010) Sheng-Nan Jiang et al. MOLECULAR THERAPY
- A synchronized quorum of genetic clocks
- (2010) Tal Danino et al. NATURE
- CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis
- (2009) Siddhartha Jaiswal et al. CELL
- CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells
- (2009) Ravindra Majeti et al. CELL
- Synthetic Gene Networks That Count
- (2009) A. E. Friedland et al. SCIENCE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started